Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof

US10526382B2 · kind B2 · utility

Assignee

• Pieris Pharmaceuticals GmbH · DE

Inventors

• Rachida Siham Bel Aiba · Munich, DE
• Andrea Allersdorfer · Wolnzach, DE
• Alexander Wiedenmann · Ulm, DE
• Christine Rothe · Freising, DE
• Shane Olwill · Freising, DE
• Hendrik Gille · Berlin, DE
• Laurent Audoly · Mahwah, US

Key dates

• Filing date: Jan 27, 2016
• Grant date: Jan 7, 2020
• Expiry date: Feb 27, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides hNGAL muteins that bind Ang-2 and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.